Patheon is the leading publicly listed provider of drug development and manufacturing services to global pharmaceutical, biotechnology and specialty pharmaceutical companies. The company's strategic vision is to become the industry's best provider of pharmaceutical development and manufacturing services.
Patheon's global manufacturing network includes approximately 6,000 employees providing services at 13 commercial contract manufacturing facilities, and 12 development centers across North America and Europe.
The company enables its customers to bring drug candidates from preclinical stages through to clinical trials, the NDA approval process and, if approved, commercial manufacturing. Patheon's development and commercial manufacturing capabilities cover primarily prescription (Rx) products in solid and sterile dosage forms, as well as specialized capabilities in high potency, controlled/sustained release, and sterile manufacturing, including aseptic filling and lyophilization.
The pharmaceutical industry is growing and, compared with other industries, is in the early stages of adopting manufacturing and development outsourcing strategies. Many global pharma, biotech and specialty pharma companies are relying on the services of contract product development and commercial manufacturing companies to help them meet growing demand and bring new drugs to market more quickly.
Patheon is the established leader in this relatively new segment of the pharmaceutical industry. With a wide range of manufacturing capabilities and significant scale in the world's two largest pharmaceutical markets – the United States and Europe – the company is uniquely positioned to serve as a strategic global manufacturing partner to the industry's leading innovators.
Patheon serves approximately 300 clients, including 18 of the 20 largest pharmaceutical companies, 9 of the top 10 biotech companies, and 7 of the 10 largest specialty pharmaceutical companies.